

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, NEW ZEALAND, CANADA, THE REPUBLIC OF SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

THIS ANNOUNCEMENT IS NOT AN OFFER FOR SALE OR SUBSCRIPTION IN ANY JURISDICTION IN WHICH SUCH OFFER, SOLICITATION OR SALE WOULD BE UNLAWFUL UNDER THE SECURITIES LAWS OF ANY SUCH JURISDICTION. THIS ANNOUNCEMENT IS NOT AN OFFER OF OR SOLICITATION TO PURCHASE OR SUBSCRIBE FOR SECURITIES IN THE UNITED STATES.

28 June 2024

**Inspiration Healthcare Group plc**  
**Posting of Circular and Notice of General Meeting**

Inspiration Healthcare Group plc (AIM: IHC) (**Inspiration Healthcare**", the "**Company**" or, together with its subsidiary undertakings, the "**Group**"), the global medical technology company pioneering specialist neonatal intensive care medical devices, is pleased to announce that, it is today posting to Shareholders the Circular convening the General Meeting in respect of the proposed Placing, Subscription and Retail Offer announced on 26 June 2024 (the "**Launch Announcement**").

The General Meeting will be held at the offices of Panmure Liberum Limited, 25 Ropemaker St, London, EC2Y 9LY at 10.30 a.m. on 22 July 2024.

The Circular will shortly be available on the Company's website: [www.inspirationhealthcaregroup.com](http://www.inspirationhealthcaregroup.com)

Capitalised terms not defined in this announcement have the meanings given to them in the Launch Announcement.

**For more information contact:**

**Inspiration Healthcare Group Plc**

Roy Davis, Executive Chairman and Interim CEO  
Alan Olby, Chief Financial Officer

Tel: +44 (0)330 175 0000

**Liberum Capital Limited (Nomad and Broker)**

Phil Walker, Richard Lindley, Will King,  
Joshua Borlant

Tel: 020 3100 2000

**Walbrook PR Ltd**

Anna Dunphy  
Stephanie Cuthbert  
Louis Ashe-Jepson

Tel: 020 7933 8780 or  
[inspirationhealthcare@walbrookpr.com](mailto:inspirationhealthcare@walbrookpr.com)  
Mob: 07876 741 001  
Mob: 07796 794 663  
Mob: 07747 515 393

**ABOUT INSPIRATION HEALTHCARE**

Inspiration Healthcare (AIM: IHC) designs, manufactures and markets pioneering medical technology. Based in the UK, the Company specialises in neonatal intensive care medical devices, which are addressing a critical need to help to save the lives and improve the outcomes of patients, starting with the very first breaths of

life.

The Company has a broad portfolio of its own products and complementary distributed products, for use in neonatal intensive care designed to support even the most premature babies throughout their hospital stay. Its own branded products range from highly sophisticated capital equipment such as ventilators for life support through to single-use disposables.

The Company sells its products directly to hospitals and healthcare providers in the UK and Ireland, where it also distributes a range of advanced medical technologies for infusion therapy. In the rest of the world the Company has an established network of distribution partners around the world giving access to more than 75 countries.

The Company operates in the UK from its Manufacturing and Technology Centre in Croydon, South London and in the USA from its facility in Melbourne, Florida.

Further information on Inspiration Healthcare can be found at [www.inspirationhealthcaregroup.com](http://www.inspirationhealthcaregroup.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@seg.com](mailto:rns@seg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NOGFZGZVGRFGDZM